Atlas Trials

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Clinical trial NCT07436858 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07436858
Sponsor
The Netherlands Cancer Institute
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Lung Cancer (NSCLC)HER2 ExpressionHER2 Gene Mutation
Start date
2026-09-07
Primary completion
2030-07-07
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.